Pregabalin is a prescription medicine with important medical uses, but it can also be misused and can cause physical dependence. In Pakistan, the medicine is widely recognised by brand names such as Gabica. Local research has documented people obtaining and using pregabalin without a prescription, while international medicine regulators have strengthened warnings about misuse, dependence, withdrawal and breathing problems.
This article explains the difference between appropriate use, misuse, dependence and addiction; the warning signs families may notice; and the treatment options a qualified clinician may consider. It also separates established evidence from what is still unknown in Pakistan. Small local studies and reports cannot tell us how common pregabalin misuse is across the whole country.
Pregabalin is a medicine used for selected neurological and mental health conditions. Whether it is helpful and safe depends on the diagnosis, dose, kidney function, other medicines and ongoing clinical review.
Pregabalin is the active ingredient. Gabica is a brand of pregabalin sold in Pakistan, while Lyrica is another trade name used internationally. A medicine pack should identify both the brand and the active ingredient, along with the capsule strength.
Products containing the same active ingredient are not an invitation to change brands, strengths or dosing on your own. Check the label every time, and ask a doctor or pharmacist before switching products. This is particularly important when several people in a household use medicines with similar-looking packaging.
Pregabalin is prescribed for neuropathic pain, which is pain caused by damaged or abnormally functioning nerves. Depending on the product authorisation and clinical setting, it may also be used as add-on treatment for certain partial-onset seizures and for generalised anxiety disorder in adults. Approved indications can differ between countries and products, so the Pakistan product information and the prescriber’s instructions should guide treatment.
Pregabalin is not a routine painkiller for every backache, headache or body pain. A clinician should confirm why it is being used and review whether it is improving the intended problem. Continued treatment should not be based only on the fact that it helps a person feel sleepy or emotionally numb.
Pregabalin is structurally related to gamma-aminobutyric acid, or GABA, but it does not work by directly stimulating GABA receptors. It binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This changes nerve signalling and can reduce abnormal pain signals and seizure activity.
The same action can also cause dizziness, sleepiness, slowed thinking or poor coordination. Pregabalin is removed mainly through the kidneys, so people with reduced kidney function may need a lower dose selected by a clinician. Taking more does not simply produce more benefit; it can increase harm.
These terms overlap, but they do not mean the same thing. Using them accurately reduces stigma and helps a clinician choose the right response.
Misuse includes taking pregabalin without a prescription, taking more or more often than directed, using somebody else’s capsules, seeking a non-medical effect such as euphoria, or combining it with other substances without clinical advice. Repeatedly using it only to sleep, relax or cope with distress can also be misuse when that is not the agreed treatment plan.
A single episode of misuse does not by itself prove addiction, but it can still cause poisoning, injury or impaired driving. Sharing prescribed capsules is unsafe because the other person’s health conditions, kidney function and medicines may be different.
Tolerance means that a person experiences less effect from the same amount and may feel an urge to increase the dose. Physical dependence means the body has adapted to regular exposure, so withdrawal symptoms may appear when the dose is reduced or stopped.
Dependence can develop during medically supervised treatment and does not automatically mean the person is addicted. It does mean that dose changes require care. Regulators now recognise that pregabalin dependence can occur at therapeutic doses as well as after misuse.
Addiction, clinically assessed as a substance use disorder, involves impaired control and continued use despite harm. Warning features include strong cravings, repeated unsuccessful attempts to cut down, spending substantial time obtaining or recovering from the medicine, and continuing despite health, family, study or work problems.
Diagnosis is based on the overall pattern rather than one sign. Someone can be physically dependent without compulsive use, while another person can show a harmful, compulsive pattern alongside tolerance and withdrawal. A non-judgmental assessment is the safest way to distinguish them.
Pakistan-specific evidence remains limited, but the evidence that does exist identifies non-prescribed access, low risk awareness and use for non-medical reasons. These findings justify better clinical review and public education without exaggerating the scale of the problem.
Local research has described people purchasing pregabalin without a prescription and starting it after advice from friends or coworkers. Some participants thought a pharmacy medicine must be harmless or free of serious side effects. That assumption is incorrect: a medicine can be legally manufactured and medically useful while still carrying dependence, withdrawal and overdose risks.
Self-medication can also hide the original problem. Persistent pain may need a neurological, musculoskeletal or metabolic assessment; anxiety and insomnia may be linked to depression, trauma, another substance or a medical condition. Using capsules without that assessment can delay appropriate care.
A 2026 qualitative study in Islamabad interviewed 15 men who were obtaining pregabalin without a prescription. Participants described peer influence, physical work demands, emotional distress, sleep problems, relaxation and perceived improvement in performance. Most had limited knowledge of pregabalin’s medical uses or risks.
That study provides useful detail about experiences, not a national prevalence estimate. Its small, all-male sample from one city cannot represent women, rural communities, other provinces or Pakistan as a whole. Other local reports and treatment-centre studies also use selected samples. Reliable nationwide data on how many people misuse pregabalin, which age groups are most affected and how trends are changing remain limited.
People with a current or past substance-use problem—particularly opioid use—require closer monitoring because regulators identify a history of substance misuse as a risk factor. Risk can also rise when a person is self-treating uncontrolled pain, anxiety, trauma, insomnia or severe stress, or when friends and coworkers normalise non-prescribed use.
Risk of medical harm is a related but separate issue. Older adults, people with kidney impairment, respiratory or neurological disease, and those taking opioids or other sedating medicines may experience serious effects at lower amounts. A clinician should assess both the risk of compulsive use and the risk of toxicity.
There is no single explanation. Understanding what the medicine is doing for the person—relieving pain, changing mood, helping sleep or modifying another drug’s effects—is essential to building a realistic treatment plan.
Some people report taking pregabalin for calmness, emotional escape, euphoria or sedation. A person may initially view this as an occasional way to unwind or sleep, then take it more regularly as tolerance develops. Chasing the original effect can lead to escalating doses and greater impairment.
Sleepiness is a medicine effect, not proof that the underlying sleep disorder is being treated. Daytime drowsiness, poor concentration and unsteady movement can increase the risk of falls, road crashes and workplace accidents, especially for drivers and people operating machinery.
Pregabalin misuse may begin with a genuine symptom. Someone with burning nerve pain, panic, grief, work stress or sleeplessness may keep increasing the dose when relief becomes incomplete. In the Islamabad study, emotional distress, fear about the future, exhausting work and poor work-life balance were among the experiences described.
Treatment must therefore look beyond the capsules. If the original pain or emotional problem is ignored, the person is left with the same trigger after withdrawal. A clinician can reassess the diagnosis and develop safer, evidence-based care for that condition.
Pregabalin may be taken with opioids to intensify sedation or other desired effects, or to cope with opioid withdrawal. It may also be combined with alcohol, sleeping tablets, anti-anxiety sedatives or sedating antihistamines. These combinations can produce more impairment than the person expects.
The main danger is additive depression of the central nervous system. Opioids and other sedatives can combine with pregabalin to suppress breathing, reduce consciousness and increase the risk of coma or death. A clinician needs an honest list of every prescribed medicine, non-prescribed drug, supplement and substance used.
No single behaviour confirms misuse. Concern becomes stronger when several changes occur together, persist over time or cause harm.
Possible warning signs include taking extra capsules, finishing a supply early, repeatedly asking for higher strengths, using several prescribers or pharmacies, and becoming distressed when the medicine is unavailable. The person may keep spare packs, conceal how much they take or give inconsistent accounts of lost prescriptions.
Cravings can appear as intense preoccupation with the next dose or an inability to follow agreed limits. These signs should prompt assessment rather than confrontation. Early requests can sometimes have another explanation, such as poorly controlled pain, but repeated escalation still requires clinical review.
Pregabalin can cause dizziness and sleepiness even when taken correctly. Greater concern arises with marked sedation, slurred speech, confusion, blurred or double vision, poor memory, slow reactions, unsteady walking or repeated falls. Swelling of the hands or feet and weight gain are recognised adverse effects that should also be discussed with a clinician.
Symptoms alone cannot show whether a person took pregabalin, another sedative or both. Sudden severe drowsiness, abnormal breathing, loss of consciousness or a seizure is an emergency, not something to observe at home until it passes.
Harmful use may lead to missed classes or shifts, falling performance, road or workplace incidents, financial pressure, arguments about medicines and withdrawal from family life. The person may stop activities that once mattered or organise the day around obtaining, taking and recovering from pregabalin.
These changes are not evidence of bad character. They may reflect intoxication, withdrawal, an untreated mental health condition or a developing substance use disorder. Documenting specific changes and their timing helps a clinician understand what is happening.
The level of risk is influenced by dose, frequency, kidney function, age, other illnesses and co-use of sedating substances. Capsules obtained from an unreliable source add the separate risk of a falsified or poor-quality product.
Dizziness and drowsiness are among the most commonly reported adverse effects. Headache, blurred vision, difficulty concentrating, impaired coordination, swelling and weight gain can also occur. A prescribed user should report effects that are persistent, worsening or interfering with normal activities.
Harmful use is suggested by a pattern: taking outside the treatment plan, escalating the amount, being repeatedly intoxicated, continuing despite injuries or other consequences, or mixing substances. A side effect can occur without misuse, and misuse can exist before obvious side effects appear.
An overdose may cause profound sleepiness, agitation, confusion, reduced consciousness or seizures. Pregabalin has also been associated with severe respiratory depression, including cases where no opioid was reported. The risk is higher when other sedatives or relevant medical conditions are present.
Call the local emergency service or go to the nearest emergency department if breathing becomes slow, shallow or difficult; the person cannot be woken; lips or skin look blue or grey; a seizure occurs; or the person collapses. Do not make the person vomit or leave them alone. Give responders the medicine packs and an honest account of all substances taken if this can be done safely.
Combining pregabalin with opioids such as tramadol or heroin, alcohol, benzodiazepines, sleeping medicines or other central nervous system depressants can increase sedation and breathing suppression. Regulatory reports include respiratory failure, coma and deaths involving pregabalin with opioids or other depressants.
Alcohol should be avoided during pregabalin treatment because it can add to drowsiness and impaired coordination. A person taking prescribed opioids or sedatives should not add, stop or alter pregabalin without the prescriber reviewing the whole combination.
People with impaired kidney function may accumulate pregabalin because it is cleared mainly by the kidneys. People over 65, those with compromised breathing or neurological disease, and those using central nervous system depressants may require dose adjustment or closer observation. Severe heart disease and a history of swelling also merit clinical review because heart failure has been reported in susceptible patients.
Pregnancy, plans for pregnancy and breastfeeding should be discussed with a qualified prescriber. Pregabalin should never be borrowed or started on a relative’s recommendation in these situations. People at risk of self-harm also need prompt assessment, because suicidal thoughts and behaviour have been reported with antiepileptic medicines, including pregabalin.
Withdrawal is a medical response to dose reduction after the body has adapted. It can occur after prescribed treatment as well as misuse and does not, on its own, prove addiction.
Reported withdrawal symptoms include insomnia, anxiety, nervousness, headache, nausea, diarrhoea, sweating, dizziness, flu-like feelings, low mood and a return or increase in pain. Some people experience strong cravings or marked restlessness. Depression, suicidal thoughts and seizures have also been reported.
The original condition may return at the same time, making it difficult to separate withdrawal from recurring pain, anxiety or sleep disturbance. A prescriber can monitor both and adjust the care plan safely.
There is no reliable single timetable that applies to everyone. The amount being taken, duration and pattern of use, previous withdrawal experiences, kidney function, other substances and physical and mental health can all influence the course. Product information notes that withdrawal severity may be related to dose.
Symptoms may occur after short-term or long-term treatment. A fixed online schedule cannot account for these differences, and a plan designed for one person may be unsafe for another.
Official product information recommends gradual discontinuation rather than abrupt stopping. Although the product information describes tapering over at least one week, a person with dependence, high-dose use, seizures, multiple substances or significant health problems may need a slower, individualised plan.
The prescriber may pause, slow or revise the taper in response to symptoms. This is not failure. The aim is to reduce harm while continuing to treat the original condition and any co-occurring substance use.
A seizure, loss of consciousness, severe confusion, hallucinations, dangerous agitation, new breathing difficulty or chest pain requires urgent medical assessment. Immediate help is also needed if the person has suicidal thoughts with intent or a plan, cannot stay safe, or has taken an overdose during a relapse.
Families should not try to manage these situations by restraining the person or giving unprescribed sedatives. Contact the local emergency service—such as Rescue 1122 where it operates—or take the person to the nearest emergency department when it is safe to do so.
There is no single symptom or routine test that establishes pregabalin dependence or addiction. Diagnosis comes from a confidential clinical history, examination and assessment of how use affects the person’s life.
The clinician will ask which product and strength are being used, how many capsules are taken, when use began, how the pattern changed and what happens after a missed dose. Prescription records, medicine packs and information from a trusted family member can help when the patient consents.
The assessment also looks for tolerance, withdrawal, cravings, failed attempts to reduce, intoxication and continued use despite harm. Honest answers lead to safer care; the purpose is treatment, not blame.
A complete review should include prescribed medicines, pharmacy purchases, herbal products, alcohol, opioids, sleeping tablets, benzodiazepines, stimulants, cannabis and tobacco. Clinicians should ask when substances are used together and whether there has been overdose, blackouts or previous withdrawal.
This information changes the risk assessment and treatment setting. Abruptly reducing several dependence-forming substances at once can carry different risks, so each substance needs an appropriate plan directed by a qualified clinician.
Assessment should cover kidney and breathing problems, seizures, heart disease, pregnancy where relevant, chronic pain and recent falls or injuries. A clinician may order tests according to the history and examination; tests support clinical decisions but do not replace the interview.
Screening for depression, anxiety, trauma, sleep disorders, psychosis, attention problems and suicidal risk is equally important. When a physical or mental health problem is driving use, treating both conditions together is more coherent than treating the capsules in isolation.
Treatment should be matched to medical risk and the person’s pattern of use. Pregabalin dependence has no universal detox formula, and evidence for a medicine that specifically cures it is limited. Safe care combines dose management with treatment of the reasons for use and support for longer-term change.
The first step is a review by a registered medical practitioner, often with psychiatric or addiction expertise. The assessment should establish current dose and timing, other substances, previous withdrawal, overdose risk, kidney function, seizure history, mental state and the safety of the home environment.
The patient should receive a clear explanation of the working diagnosis and options. If there is severe intoxication, respiratory compromise, a seizure, psychosis or imminent self-harm risk, stabilisation in an emergency or hospital setting takes priority over a routine clinic appointment.
For many physically dependent patients, treatment involves a gradual, clinician-supervised reduction. The starting point and pace must be individualised. A responsible article or clinic should not prescribe a fixed milligram-by-milligram schedule without examining the patient.
During a taper, the clinician monitors withdrawal, sleep, mood, pain, seizures, other substance use and adherence. “Medical detoxification” means managing this withdrawal safely; it may occur as an outpatient or inpatient depending on risk. Detox is an initial phase, not a complete treatment for compulsive use or unresolved pain and distress.
Psychological treatment can help a person identify triggers, challenge beliefs about the medicine, plan for cravings, manage stress and rebuild routines. Approaches used in substance-use care include motivational and cognitive-behavioural techniques, but the plan should match the person’s needs rather than rely on a branded programme or guaranteed claim.
Therapy may address peer pressure, workplace fatigue, family conflict, grief, trauma and easy access to medicine. Practical skills—delaying action on a craving, contacting support, leaving a high-risk situation and following a written emergency plan—can make recovery more manageable.
Dual-diagnosis care addresses a substance use disorder and a mental health condition at the same time. This matters when pregabalin is being used to suppress anxiety, depression, trauma symptoms or insomnia. Treating only one side can leave the other condition as a continuing trigger.
Integrated care requires communication between the prescriber and psychological team. Medicines for co-occurring conditions must be selected carefully to avoid unnecessary sedation, interactions or another dependence problem.
Outpatient treatment may be appropriate when the person is medically stable, can attend frequent reviews, has a safe home environment and does not have severe withdrawal or uncontrolled polysubstance use. It allows the person to remain connected to family, education or work while receiving structured care.
Inpatient or hospital-based care may be considered for high-risk withdrawal, serious medical or psychiatric illness, repeated overdose, significant use of several substances, previous seizures, inability to remain safe or lack of reliable support. Admission should follow an individual assessment; being dependent on pregabalin does not automatically mean every person needs residential treatment.
Recovery is more than completing a taper. It involves improving health and daily functioning while reducing the situations that made harmful use likely.
The original diagnosis should be reassessed rather than assumed. Neuropathic pain may require treatment of its cause plus physical rehabilitation, psychological pain-management strategies or another clinician-selected medicine. Anxiety, depression and insomnia may respond to structured psychological care, sleep interventions and appropriate non-dependence-forming treatment.
A replacement should never be chosen only because it feels sedating. The goal is sustained improvement in pain, mood, sleep and functioning with the lowest practical risk.
A relapse-prevention plan identifies people, places, feelings and routines linked to use. It can specify whom to call, how to leave a situation where capsules are offered, what to do after a poor night’s sleep and how prescriptions will be collected and stored.
Stress management may include a regular sleep schedule, meals, physical activity suited to the person’s health, brief relaxation exercises and planned breaks from exhausting work. These tools support treatment but do not replace medical care for withdrawal or severe mental illness.
Follow-up allows the team to review cravings, mood, pain, sleep, other substance use and return to normal responsibilities. Appointment frequency can change as stability improves. With consent, a trusted family member may help notice early warning signs and support the medication plan.
A lapse should prompt rapid contact with the clinician, especially if tolerance has fallen or opioids and sedatives are involved. It does not erase earlier progress; it shows that the risk plan, treatment intensity or underlying-condition care may need adjustment.
Recovery goals should be practical and gradual: regular attendance, safe travel, manageable workload, financial routines and reconnection with supportive people. Someone whose job involves driving, heights or machinery may need medical clearance if dizziness, sedation or poor coordination persists.
Where possible, the patient and clinician can agree on a staged return and limited disclosure that respects privacy. Daily structure can support recovery, but pushing a person back into unsafe demands before stabilisation can recreate the same triggers that contributed to misuse.
Families can support access to care and reduce immediate risks, but they cannot diagnose or force lasting recovery on their own.
Choose a time when the person is awake, not intoxicated and the setting is calm. Describe specific observations: “You have been very drowsy and have run out early twice,” rather than using labels or making accusations. Express concern and propose one concrete next step, such as an appointment with a registered doctor.
Listen for what the medicine is doing for the person. Pain, fear, sleep and withdrawal may be powerful drivers. Taking those problems seriously does not mean approving unsafe use.
Families can help arrange an assessment, share an accurate history with consent, attend education sessions and support follow-up. They can also protect children and vulnerable adults from access to medicines and avoid offering alcohol or sedating drugs.
Do not shame, threaten or physically punish the person. Do not buy extra capsules to avoid an argument, give somebody else’s prescription, or demand abrupt cessation when dependence may be present. If there is violence or immediate danger, prioritise safety and contact emergency or appropriate local services.
Keep pregabalin in its original labelled pack in a locked place, record supplies if the patient and clinician agree, and never share it. A family member can assist with dispensing only as part of a consensual clinical plan; covert medication or improvised dose changes can be dangerous.
Write down emergency signs, the nearest emergency department, available transport and current medicines. Families should know that extreme sleepiness, slow or shallow breathing, blue or grey lips, collapse, seizure or suicidal intent requires immediate help.
Quality varies between services. Look for transparent, licensed, medically supervised care and a plan that includes assessment, withdrawal management and follow-up.
A registered medical practitioner should oversee diagnosis, medical risk and dose reduction. A psychiatrist or clinician with addiction experience may be particularly useful when there is compulsive use, another substance, severe anxiety, depression, psychosis or suicidal risk. A clinical psychologist or appropriately trained therapist can provide structured psychological care.
Nurses and pharmacists support monitoring and medicine safety. Depending on the original condition, the team may also need a neurologist, pain specialist, physician, physiotherapist or other relevant clinician. One provider does not need every professional on site, but should have a clear referral pathway.
Verify the doctor’s current registration through the Pakistan Medical and Dental Council’s public register. Ask for the facility’s licence and check it with the relevant provincial or territorial healthcare regulator, such as the healthcare commission or authority responsible for the location.
A website, social-media page or use of the word “rehab” is not evidence of clinical approval. Confirm the physical address, responsible doctor, emergency arrangements and complaint procedure before admission or payment.
Ask who performs the first assessment, who prescribes the taper, how night-time emergencies are handled and when hospital transfer occurs. Ask whether the service treats opioid, alcohol or sedative use at the same time and how it manages kidney disease, seizures and suicide risk.
Also ask how consent, confidentiality, family contact, discharge and records are handled. A credible service should explain likely benefits and risks, avoid a guaranteed-cure promise and provide a written aftercare plan rather than presenting detox as the end of treatment.
Costs vary by city, level of medical care, outpatient or residential setting, room type, investigations, medicines and length of follow-up. Request a written breakdown covering assessment, professional fees, laboratory tests, medicines, accommodation, emergency transfers and aftercare. Ask which charges could change and what refund terms apply.
Contact public hospitals, teaching hospitals and private services to ask what programmes are actually available locally. A higher price does not prove higher quality; registration, medical staffing, safety systems and continuity of care are more meaningful checks.
Prevention requires action by prescribers, pharmacists, regulators, patients, families and communities. It should protect access for legitimate patients while reducing unreviewed and non-prescribed use.
Prescribers should confirm a recognised indication, review kidney function and concurrent sedatives, explain drowsiness and driving risk, and discuss dependence and withdrawal before treatment. The lowest appropriate dose and regular review can help identify limited benefit, dose escalation or early refill requests.
When treatment is no longer beneficial, a planned reduction is safer than repeated automatic refills or abrupt stopping. Patients should be invited to discuss cravings or extra use honestly without fear of being abandoned.
Pharmacies should follow current Pakistan and local drug-sale requirements, use qualified staff and refer requests that raise safety concerns to a prescriber. They should not treat a familiar brand name as proof that repeat, high-strength or third-party purchases are safe.
Better prescription and dispensing records can help identify duplicate supply and unsafe combinations. The exact legal scheduling and monitoring arrangements can change and may differ by jurisdiction, so professionals should consult current DRAP and provincial rules rather than rely on old news reports.
Store pregabalin out of sight and reach of children, in its original packaging, and do not share or sell unused capsules. Ask a pharmacist how to dispose of unwanted or expired medicine safely; do not leave loose capsules in household rubbish or flush them without local professional advice.
Buy medicines from a licensed pharmacy and inspect the pack, batch information and condition. DRAP publishes safety and rapid alerts, including alerts about suspected spurious Gabica products. Patients, families and pharmacists should check current alerts and report suspected quality problems through the appropriate DRAP channel.
Public messages should explain that “prescription medicine” does not mean “risk-free,” while avoiding panic about legitimate treatment. People need clear information about sedation, mixing substances, dependence, gradual discontinuation and emergency breathing signs.
Stigma can delay honest disclosure and treatment. Using terms such as “person experiencing dependence” and focusing on observable risk makes it easier for patients and families to seek qualified help early.
Gabica is a brand name for a medicine containing pregabalin. Pregabalin is the active ingredient; Lyrica and other products are different brand names. Always check the active ingredient and strength on the pack, and do not switch strengths or dosing without a doctor or pharmacist.
Yes. Physical dependence and withdrawal can occur at therapeutic doses, especially with ongoing use. This is not automatically addiction. Addiction involves a broader pattern of impaired control and continued use despite harm. Report cravings, extra dosing or difficulty following the plan to the prescriber early.
Do not stop regular pregabalin suddenly without consulting a qualified clinician. Abrupt discontinuation can cause withdrawal and may be particularly risky for someone with epilepsy, high-dose use, multiple substances or serious health conditions. A clinician can design and monitor an individual taper.
There is no fixed duration that is accurate for everyone. The dose, length and pattern of use, kidney function, other substances, health conditions and taper speed can affect symptoms. Product information recommends gradual discontinuation, but a person with dependence may need a longer plan decided through clinical review.
Yes. Alcohol and tramadol can add to pregabalin’s sedating effects. Tramadol is an opioid, and using pregabalin with opioids or other central nervous system depressants can increase the risk of severe drowsiness, respiratory depression, coma and death. Do not combine them unless a prescriber who knows all current medicines has specifically assessed the treatment.
Seek immediate help if the person has slow, shallow or difficult breathing; cannot be woken; has blue or grey lips or skin; collapses; has a seizure; develops severe confusion or hallucinations; or has suicidal intent or a plan. Call the local emergency service or go to the nearest emergency department, and take the medicine packaging and details of other substances if safe.
Pregabalin can be a valuable treatment when it is prescribed for the right reason and reviewed properly. Misuse and dependence are treatable health problems. Early, honest discussion with a registered clinician gives the patient the best chance of reducing risk while still receiving care for pain, anxiety, seizures, sleep problems or other needs.
